Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors

Inflammation may underlie cancer‐related fatigue; however, there are no studies that assess the relation between fatigue and cytokines in patients with advanced disease versus patients without disease activity. Furthermore, the relation between cytokines and the separate dimensions of fatigue is unknown. Here, association of plasma levels of inflammatory markers with physical fatigue and mental fatigue was explored in advanced cancer patients and cancer survivors.

[1]  R. Timman,et al.  Differences in fatigue experiences among patients with advanced cancer, cancer survivors, and the general population. , 2012, Journal of pain and symptom management.

[2]  J. Rigas,et al.  A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer , 2011, Expert opinion on biological therapy.

[3]  M. Irwin,et al.  Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Ingrid J Orre,et al.  Higher levels of fatigue are associated with higher CRP levels in disease-free breast cancer survivors. , 2011, Journal of psychosomatic research.

[5]  B. Laird,et al.  Pain, depression, and fatigue as a symptom cluster in advanced cancer. , 2011, Journal of pain and symptom management.

[6]  R. Kurzrock,et al.  Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra) , 2010, Molecular Cancer Therapeutics.

[7]  Stoyan Dimitrov,et al.  Effects of sleep and circadian rhythm on the human immune system , 2010, Annals of the New York Academy of Sciences.

[8]  Ingrid J Orre,et al.  Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue , 2009, Brain, Behavior, and Immunity.

[9]  J. Stolzenburg,et al.  Fatigue in Cancer Survivors – Prevalence and Correlates , 2009, Oncology Research and Treatment.

[10]  I. Tannock,et al.  Cytokines and their relationship to the symptoms and outcome of cancer , 2008, Nature Reviews Cancer.

[11]  S. Ancoli-Israel,et al.  Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Akechi,et al.  Plasma interleukin-6 and fatigue in terminally ill cancer patients. , 2008, Journal of pain and symptom management.

[13]  L. Natarajan,et al.  The association between fatigue and inflammatory marker levels in cancer patients: A quantitative review , 2007, Brain, Behavior, and Immunity.

[14]  Kevin Fiscella,et al.  Mechanisms of cancer-related fatigue. , 2007, The oncologist.

[15]  P. Jean-Pierre,et al.  Cancer-related fatigue: the scale of the problem. , 2007, The oncologist.

[16]  M. Groenvold,et al.  Multidimensional measurement of fatigue in advanced cancer patients in palliative care: an application of the multidimensional fatigue inventory. , 2006, Journal of pain and symptom management.

[17]  M. Irwin,et al.  Inflammatory biomarkers for persistent fatigue in breast cancer survivors , 2006, Brain, Behavior, and Immunity.

[18]  G. Mantovani,et al.  A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress , 2006, Cancer Epidemiology Biomarkers & Prevention.

[19]  Stefano Iacobelli,et al.  Elevated Serum Cytokines Correlated with Altered Behavior, Serum Cortisol Rhythm, and Dampened 24-Hour Rest-Activity Patterns in Patients with Metastatic Colorectal Cancer , 2005, Clinical Cancer Research.

[20]  E. Thiel,et al.  Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  A. Hinz,et al.  Fatigue in the General Population , 2003, Oncology Research and Treatment.

[22]  Patricia A. Ganz,et al.  Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors , 2002, Psychosomatic medicine.

[23]  S. Kvaløy,et al.  High level of fatigue in lymphoma patients treated with high dose therapy. , 2000, Journal of pain and symptom management.

[24]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[25]  C. Gabay,et al.  Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. , 1997, The Journal of clinical investigation.

[26]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[27]  R. Crow,et al.  A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals , 1996, Supportive Care in Cancer.

[28]  E. Smets,et al.  The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. , 1995, Journal of psychosomatic research.

[29]  S. Sleijfer,et al.  The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator? , 2008, European journal of cancer.

[30]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .